Daiyong Deng

Daiyong Deng

Auto-generated profile, based on publicly available information

Daiyong Deng

Rutgers University New Jersey Medical School 1 Department of Microbiology, Biochemistry and Molecular Genetics Newark, NJ

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2024 in Journal of Experimental Medicine
Verified
Journal Article
Open access
DDDaiyong Deng
Daiyong Deng
HBHabeebunnisa Begum
Habeebunnisa Begum
TLTong Liu
Tong Liu
JZJiangyan Zhang
Jiangyan Zhang
QZQiang Zhang
Qiang Zhang
PHPingping Hou
Pingping Hou
Resistance to KRAS therapy in pancreatic ductal adenocarcinoma (PDAC) involves cellular plasticity, particularly the epithelial-to-mesenchymal transition (EMT), which poses challenges for effective targeting. Chronic pancreatitis, a known risk factor for PDAC, elevates TGFβ levels in the tumor microenvironment (TME), promoting resistance to KRAS therapy. Mechanistically, TGFβ induces the formation of a novel protein complex composed of SMAD3, SMAD4, and the nuclear factor NFAT5, triggering EMT and resistance by activating key mediators such as S100A4. Inhibiting NFAT5 attenuates pancreatitis-induced resistance to KRAS inhibition and extends mouse survival. Additionally, TGFβ stimulates PDAC cells to secrete CCL2, recruiting macrophages that contribute to KRAS bypass through paracrine S100A4. Our findings elucidate the role of TGFβ signaling in EMT-associated KRAS therapy resistance and identify NFAT5 as a druggable target. Targeting NFAT5 could disrupt this regulatory network, offering a potential avenue for preventing resistance in PDAC.